Editorial: Scientific Advisors to the Editors

Abstract

The continued success of the Journal of Pharmaceutical Sciences (JPharmSci®) in publishing the most original and significant scientific research findings in the pharmaceutical sciences is dependent in large part on the exceptional contributions of our Editorial Advisory Board (EAB) in the manuscript review process. The EAB members also participate in the annual selection of Ebert Prize candidates for the American Pharmacists Association and provide guidance to the Editorial Team on current and emerging trends in the pharmaceutical sciences. The JPharmSci® Editorial Team is pleased to announce the re-appointment to the EAB for another 3-year term (January 1, 2021 to December 31, 2023) of the following individuals: Carmen Alvarez-Lorenzo, Universidade de Santiago de Compostela; Cory Berkland, The University of Kansas; Akhilesh Bhambhani, Merck & Co., Inc.; Mino R. Caira, University of Cape Town; Carla M. Caramella, University of Pavia; Merry Christie, Voisin Consulting Life Sciences; Carsten Ehrhardt, Trinity College Dublin; David Elder, David P Elder Consultancy; Igor Gonda, Respidex LLC; Sarah Gordon, Liverpool John Moores University; Richard H. Guy, University of Bath; David J. Hauss, Regeneron Pharmaceuticals, Inc.; Rene Holm, Janssen Pharmaceutica; Munir A. Husssain, MAH Pharma Consulting LLC; Wim Jiskoot, Leiden University; Yukio Kato, Kanazawa University; Bruce Kerwin, Just-Evotec Biologics; Gregory Knipp, Purdue University; William J. Lambert, Module 3 Pharmaceutical Consulting; David Lechuga-Ballesteros, AstraZeneca Pharmaceuticals LP; S. Kevin Li, University of Cincinnati; Hanns-Christian Mahler, Lonza AG; Toru Maruyama, Kumamoto University; Gary McGeorge, Bristol-Myers Squibb; Patrick J. McNamara, University of Kentucky; Natalie Medlicott, University of Otago; José Ramón Moyano-Méndez, University of Seville; Eric Munson, Purdue University; Amber Haynes Raines, KBI Biopharma; Jukka Rantanen, University of Copenhagen; Larry Rosen, Venatorx Pharmaceuticals; Habil. Christoph Saal; Merck KGaA; Christian Schöneich, The University of Kansas; David Spencer, Ipsen; Robert M. Straubinger, University at Buffalo; Changquan Calvin Sun, University of Minnesota; Raj Suryanarayanan, University of Minnesota; Lynne Taylor, Purdue University; Frank-Peter Theil, UCB Biopharma; Masatoshi Tomi, Keio University; Nicolas Tsapis, Université Paris-Saclay; Guy Van den Mooter, University of Leuven; Michel Vert, CNRS – University of Montpellier; Nicholas W. Warne, Pfizer; and Kouichi Yoshinari, University of Shizuoka. The JPharmSci® Editorial Team would like to publicly thank the following individuals who have served on the JPharmSci® EAB and who will retire from the EAB effective December 31, 2020: Sunny Bhardwaj, Merck & Co.; Maria Jose Cocero Alonso, Universidad Valladolid; Xavier Decleves, Université Paris Descartes; Barrie C. Finnin, Monash University; Yatin Gokarn, Sanofi; Hiroyuki Kusuhara, University of Tokyo; Masanori Tachikawa, University of Tokushima; Mikihisa Takano, Hiroshima University; Yasuo Tsutsumi, Osaka University; Timothy Wiedmann, University of Minnesota; and Akira Yamamoto, Kyoto Pharmaceutical University. We are also pleased to announce the appointment of new EAB members for 3-year terms starting on January 1, 2021. These new members of the JPharmSci® EAB include: Shin-ichi Akanuma, University of Toyama; Marianne Ashford, AstraZeneca; Sudip K. Das, Butler University; Camilla Foged, University of Copenhagen; Akiko Ishii-Watabe, National Institute of Health Sciences; Wooin Lee, Seoul National University; Wilna Liebenberg. North-West University; Wei Qi, Amgen Inc.; and Natalie Trevaskis, Monash University. Together with the re-appointments and new appointments, the JPharmSci® EAB membership is now at 234 members. The JPharmSci®’s Editorial Team believes that the composition of the EAB appropriately reflects the diversity of scientific disciplines served by the journal and the diversity of its international audience. In addition, we feel that the EAB is sufficiently large to ensure that an adequate number of experts are available to conduct timely reviews of the approximately 1200 manuscripts per year that are submitted to JPharmSci®. Finally, as EIC I would like to take this opportunity to thank all of the EAB members, the Editors, and the Editorial Office Staff for their dedication to the success of JPharmSci® this past year and going forward into 2021. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Erratum to “Editorial: Scientific advisors to the editors” [J Pharm Sci 110 (2021) 988]Journal of Pharmaceutical SciencesVol. 110Issue 4PreviewThe title of the Editorial was mistakenly reversed with another Editorial in both the Table of Contents and on the papers themselves in the March 2021 issue of the Journal of Pharmaceutical Sciences. Full-Text PDF